Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer

Dubay, Rachel A; Rose, Peter G.; O’Malley, David M.; Shalodi, Abdelwahab D.; Ludin, Adir; Selim, Mostafa A.

doi:10.1016/j.ygyno.2004.03.034

Cited by 30 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…cervical cancer), low dose chemotherapy concurrently with radiotherapy has clearly been demonstrated to produce a radiosensitizing effect (Dubay et al, 2004;Keys et al, 1999;Rose et al, 1999). Furthermore, a recent retrospective clinical study of patients with GBM treated only with concurrent radiotherapy and TMZ, and omitting the adjuvant TMZ component, suggests that the concomitant rather A c c e p t e d m a n u s c r i p t 24 than the adjuvant phase is the most efficacious part, raising the question of the optimal timing of chemotherapy in the treatment of GBM (Sridhar et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects

Barazzuol

Burnet

Jena

et al. 2010

Journal of Theoretical Biology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects

Barazzuol

Burnet

Jena

et al. 2010

Journal of Theoretical Biology

View full text Add to dashboard Cite

“…Compared with cisplatin, carboplatin is now used as an effective treatment regimen with an improved toxicity profile in ovarian cancer patients [10]. Despite this evidence, only a few small clinical trials of carboplatin-based chemoradiotherapy (CarboRT) in cervical cancer patients have been reported [11][12][13][14][15]. To our knowledge, there have been no reports comparing CarboRT with CisRT.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Carboplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks

et al. 2013

View full text Add to dashboard Cite

Purpose. The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) Implications for Practice: Cisplatin-based chemoradiotherapy (CisRT) has been regarded as the standard treatment for patients with locally advanced cervical cancer. Cisplatin, however, can cause nephrotoxicity, has highly emetogenic effects, and creates the need for a large amount of hydration. Carboplatin-based chemoradiotherapy was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.

show abstract

“…More than 85% of these cases and deaths occur in the developing countries, including China [1]. Concurrent chemoradiation therapy is the standard therapy used most often for patients with cervical squamous cell carcinoma (CSCC) who have locally advanced [2], [3] and recurrent and/or metastatic [4] diseases. However, primary or acquired chemoresistance is a serious clinical problem that contributes to disease recurrence, progression and disease-specific mortality [5]–[7].…”

Section: Introductionmentioning

confidence: 99%

RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer

Shi

Yang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

RAD52 is an important but not well characterized homologous recombination repair gene that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants in the response of tumor cells to platinum agents, we investigated their associations with platinum resistance and prognosis in cervical cancer patients. We enrolled 154 patients with cervical squamous cell carcinoma, who had radical surgery between 2008 and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT and immunohistochemistry methods, respectively. In 144 cases who had genotyping data, we found that both the rs1051669 variant and RAD52 protein expression were significantly associated with carboplatin resistance (P = 0.024 and 0.028, respectively) and rs10774474 with nedaplatin resistance (P = 0.018). The rs1051669 variant was significantly associated with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4−16.1, P = 0.013). When these three RAD52 variants were combined, progression-free survival was lower in patients who carried at least one (≥1) variant allele compared to those without any of the variant alleles (P = 0.047). Therefore, both RAD52 variants and protein expression can predict platinum resistance, and RAD52 variants appeared to predict prognosis in cervical cancer patients. Large studies are warranted to validate these findings.

show abstract

Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer

Cited by 30 publications

References 17 publications

A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects

A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects

Comparison of Carboplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks

RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer

Contact Info

Product

Resources

About